Kevin Kunzmann

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

Finerenone (Kerendia) may help reduce the decline in estimated glomerular filtration rates (eGFRs) in patients with chronic kidney disease (CKD) who have been hospitalized due to heart failure (HF).

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.

From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.

New ACOG 2024 data suggest SARS-CoV-2 in the early stages of pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

National survey data presented at ACOG 2024 shows many medical students applying for OB/GYN residencies prioritized states with abortion access.

With incidence climbing amid climate change, an emergency medicine doctor has advice on prevention of cardiovascular and dermatologic effects.